Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-10-23
2007-10-23
Kifle, Bruck (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C544S359000, C544S360000, C544S383000, C544S392000, C544S398000
Reexamination Certificate
active
11265030
ABSTRACT:
Compounds with 5HT7receptor affinity (some of which are novel) useful for lowering IOP, improving blood flow to the optic nerve head and the retina, providing neuroprotection, and treating retinal diseases are disclosed. The Compounds are also useful for treating sleep disorders, depression, and other psychiatric disorders, such as, schizophrenia, anxiety, obsessive compulsive disorder, circadian rhythm disorders, and centrally and peripherally mediated hypertension. Compositions and methods for their use are also disclosed.
REFERENCES:
patent: 3303189 (1967-02-01), Loev
patent: 4330542 (1982-05-01), Descamps et al.
patent: 5011846 (1991-04-01), Gittos et al.
patent: 5106855 (1992-04-01), McLees
patent: 5130313 (1992-07-01), Comte et al.
patent: 5153192 (1992-10-01), Dean et al.
patent: 5290781 (1994-03-01), Espino et al.
patent: 5344929 (1994-09-01), Dean et al.
patent: 5470973 (1995-11-01), Hoff
patent: 5494928 (1996-02-01), Bös
patent: 5538966 (1996-07-01), May et al.
patent: 5538974 (1996-07-01), Ogawa et al.
patent: 5561150 (1996-10-01), Wichmann
patent: 5646173 (1997-07-01), Bös et al.
patent: 5652272 (1997-07-01), Ogawa et al.
patent: 5693654 (1997-12-01), Birch
patent: 5773437 (1998-06-01), Masaki et al.
patent: 5874429 (1999-02-01), Mizuno et al.
patent: 5880134 (1999-03-01), Cohen et al.
patent: 5902815 (1999-05-01), Olney et al.
patent: 6107324 (2000-08-01), Behan et al.
patent: 6271223 (2001-08-01), Mizuno et al.
patent: 6660870 (2003-12-01), Ruskinko et al.
patent: 6664286 (2003-12-01), May et al.
patent: 6696476 (2004-02-01), Chen et al.
patent: 6806285 (2004-10-01), May et al.
patent: 6884816 (2005-04-01), May et al.
patent: 2003/0181503 (2003-09-01), May et al.
patent: 0522226 (1993-01-01), None
patent: 0738513 (1996-10-01), None
patent: 0771563 (1997-05-01), None
patent: 37010770 (1962-08-01), None
patent: WO92/19606 (1992-11-01), None
patent: WO92/20338 (1992-11-01), None
patent: WO94/03162 (1994-02-01), None
patent: WO95/19981 (1995-07-01), None
patent: WO97/17345 (1997-05-01), None
patent: WO97/29097 (1997-08-01), None
patent: WO97/48681 (1997-12-01), None
patent: WO97/49695 (1997-12-01), None
patent: WO98/00400 (1998-01-01), None
patent: WO98/18458 (1998-05-01), None
patent: WO99/59499 (1999-11-01), None
patent: WO 00/12475 (2000-03-01), None
patent: WO 00/12510 (2000-03-01), None
patent: WO 00/35922 (2000-06-01), None
patent: WO 00/44753 (2000-08-01), None
patent: WO 01/40183 (2001-06-01), None
patent: WO 01/70207 (2001-09-01), None
patent: WO 01/70223 (2001-09-01), None
patent: WO 01/70230 (2001-09-01), None
patent: WO 01/70701 (2001-09-01), None
patent: WO 01/70702 (2001-09-01), None
patent: WO 01/70745 (2001-09-01), None
patent: WO 02/098350 (2002-12-01), None
patent: WO 02/098400 (2002-12-01), None
patent: WO 02/098860 (2002-12-01), None
patent: WO 03/051291 (2003-06-01), None
patent: WO 03/051352 (2003-06-01), None
patent: WO 03/053436 (2003-07-01), None
patent: WO 2004/019874 (2004-03-01), None
patent: WO 2004/028451 (2004-04-01), None
patent: WO 2004/054572 (2004-07-01), None
patent: WO 2004/058725 (2004-07-01), None
Nesmeyanov et al. (Doklady Akademii Nauk SSSR (1961), 136, 836-9). Abstract.
Goldenberg et al. European Journal of Medicinal Chemistry (1980), 15(6), 545-50. Abstract.
Ahmad, “Fluoxetine and glaucoma,”Annals of Pharmacother., vol. 25:436, (1992).
Barnet and Osborne, “The Presence of Serotonin (5-HT1) Receptors Negatively Coupled to Adenylate Cyclase in Rabbit and Human Iris-Ciliary Processes,”Exp. Eye Res., vol. 57:209-216 (1993).
Chang et al., “Mechanism of the Ocular Hypotensive Action of Ketanserin,”J. Ocular Pharmacol, vol. 1(2):137-147 (1985).
Chidlow et al., “Characteristics of [3H]5-Hydroxytryptamine Binding to Iris—Cilary Body Tissue of the Rabbit,”Invest. Ophthalmol. Vis. Sci., 36(11):2238-2245 (1995).
Chiou et al., “Effects of Antiglaucoma Drugs on Ocular Blood Flow in Ocular Hypertension Rabbits,”J. Ocular Pharmacol, vol. 9(1):13-24 (1993).
Costagliola et al., “Effect of Oral Ketanserin Administration on Intraocular Pressure in Glaucomatous Patients,”Ex. Eye Res., vol. 52:507-510 (1991).
Costagliola et al., “Fluoxetine Oral Administration Increases Intraocular Pressure,”Br. J. Ophthalmol., vol. 80:678 (1996).
Eglen et al., “The 5-HT7Receptor: Orphan Found,”Trend Pharmacol. Sci., vol. 18:104-107 (1997).
Gupta et al., “Therapeutic Potentials of 5-HT Receptor Modulators,” Indian J. of Pharmacology, vol. 26, pp. 94-107 (1994).
Heidmann et al, Four-5-Hydroxytryptamine7(5-HT7) Receptor Isoforms in Human and Rat Produced by Alternative Splicing: Species Differences Due to Altered Intron-Exon Organization,J. Neurochem, vol. 68(4): 1372-1381 (1997).
Hoyer et al., “VII. International Union of Pharmacology Classification of Receptors for 5-Hydroxytryptamine (Serotonin),”Pharmacol Rev., vol. 46(2):157-203 (1994).
Jae et al., “Pyrrolidine-3-carboxylic Acids as Endothelin Antagonists. 2. Sulfonamide BasedETA/ETBMixed Antagonists,”J. Med. Chem., vol. 40:3217-3227 (1997).
Krootila et al., “Effect of Serotonin and Its Antagonist (Ketanserin) on Intraocular Pressue in the Rabbit,”J. Ocular Pharmacol., vol. 3(4):279-290 (1987).
Mallorga et al., “characterizationof serotonin receptors in the iris + ciliary body of the albino rabbit,”Curr. Eye Res., vol. 6(3):527-532 (1987).
Mano et al. “The Effect of Anplag (Sarpogrelate HCI), New Selective 5-HT2Antagonist on Intraocular Pressure in Rabbits,”Invest. Opthal. Vis. Sci., vol. 36(Suppl):3322- (1995).
Martin et al., “Serotonin in Human Aqueous Humor,”Ophthalmol., vol. 95(9):1221-1226 (1988).
Martin et al., “The structure and signalling properties of 5-HT receptors: an endless diversity?”,Trends in Pharamacological Science, vol. 19, pp. 2-4 (1998).
May et al., “A Novel and Selective 5-HT2Receptor Agonist with Ocular Hypotensive Activity: (S)-(+)-1-(2-Aminopropyl)-8,9-dihydropyrano[3,2-e]indole,”J. Med. Chem., vol. 46, pp. 4188-4195 (2003).
May et al., “Evaluation of the Ocular Hypotension Response of Serotonin 5-HT1Aand 5-HT2Receptor Ligands in Conscious Ocular Hypertensive Cynomolgus Monkeys,”J. of Pharmacology and Experimental Therapeutics, vol. 306(1), pp. 301-309 (2003).
Meyer et al., Topical Application of Serotonin or the 5-HT1-Agonist 5-CT Intraocular Pressure in Rabbits,Invest. Ophthalmol. Vis. Sci., vol. 34(1):3035-3042 (1993).
Osborne et al., “Do-Beta Adrenoceptors and Serotonin 5-HT1AReceptors Have Similar Functions in the Control of Intraocular Pressure in the Rabbit?”,Ophthalmologica, vol. 210-308-314 (1996).
Osborne et al., “5-Hydroxytryptamine1Aagoists: potential use in glaucoma. Evicence from animal studies,”Eye, vol. 14(38), pp. 454-463 (2000).
Sianesi et al., “New Benzothiazines. 4.11H-2,3-Benzothiazin-4(3H)-one,2,2-Dioxide and 2H-1,2-Benzothiazin-3(4H)-one 1,1-Dioxide Nitrogen Derivatives with Central Nervous System Activity,”J. of Medicinal Chemistry, vol. 16(10), pp. 1133-1137 (1973).
Takenaka et al., “The Effect of Anplag (Sarporelate HCL), Novel Selective 5-HT2Antagonist on Intraocular Pressure in Glaucoma Patients,”Invest Ophthal. Vis. SCi., vol. 36 (Suppl):3390-377, (1995).
Tobin et al., “Evidence for the Presence of Serotonergic Nerves and Receptors in the Iris-Ciliary Body J. Complex of Rabbit,”J. of Neurosci., vol. 8(10):3713-3721 (1988).
Tobin et al., “Evidence for the Presence of Serotonin Receptors Negatively Coupled to Adenylate Cyclase in the Rabbit Iris-Ciliary Body,”J. Neurochem., vol. 53(3):686-601, 1989.
Wang et al., “Effect of 5-methylurapidil, an α1a-adrenergic antagonist and 5-hydroxytryptamine1aagonist, on aqueous humor dynamics in monkeys and rabbits,”Curr. Eye Res., vol. 16:769-775 (1997).
Wang et al., Effect ofp-MPPI Hydrochloride (p-MPPI) Applid Before 5-methylurapidil (5-MU) on Intraocula
Chen Hwang-Hsing
Dean Thomas R.
May Jesse A.
Sharif Najam A.
Alcon Manufacturing Ltd.
Kifle Bruck
Ryan Patrick M.
LandOfFree
Serotonergic 5HT 7 receptor compounds for treating ocular... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Serotonergic 5HT 7 receptor compounds for treating ocular..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Serotonergic 5HT 7 receptor compounds for treating ocular... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3853962